????? ?? ?? ? ??? ????????????? ????????????????? ???????????????????gene in patients relapsing right after treatment method While using the BCL2 antagonist venetoclax. 66 Resistance to these agents continues to be connected with these mutations in all around 70% of scenarios, Whilst they are usually subclonal as well as their specific role causing